miRoncol Health
Oncology · Published research foundation

Where the platform became a focused test.

miRoncol’s oncology research established the company’s first evidence-backed application of microRNA intelligence. That work is now presented through miCheckup, the dedicated Early Cancer Detection Test.

First focused applicationOncology
Illustration of microRNA molecules circulating with blood cells

An Early Cancer Detection Test grounded in the first peer-reviewed publication of a miRNA-based multi-cancer early detection model.

Testing details, eligibility, clinical information, ordering and product-specific disclosures belong on the dedicated miCheckup website.

miRoncol Health

The company and intelligence platform

Develops microRNA measurement, AI-assisted pattern analysis, longitudinal research and the broader application portfolio.

miCheckup

The Early Cancer Detection Test

Provides the cancer-specific test experience, including who it is for, how it works, ordering and important clinical information.

Evidence before assertion

The oncology branch begins with published research.

Two peer-reviewed studies form the public scientific foundation for miRoncol’s blood-based microRNA approach to multi-cancer detection.

Published research does not by itself establish performance for every population, sample type or intended use. Product-specific validation and disclosures are provided through miCheckup.

Why this biological layer

Cancer is one application of microRNA intelligence.

microRNAs participate in post-transcriptional gene regulation. Evaluating patterns across this regulatory layer may add information that differs from a single downstream biomarker or a structural image.

A healthcare professional collecting a blood sample
Current oncology application The miCheckup test begins with a blood sample.
01

Regulatory patterns

The approach evaluates disease-associated patterns within the microRNA profile.

AI

Computational interpretation

AI-assisted models help recognize disease-associated patterns within the microRNA profile.

CTX

Clinical context

A screening signal is information for appropriate follow-up, not a standalone diagnosis or treatment decision.

From research to application

A focused test is built through successive evidence.

The public product is the end of a translation pathway. It is not simply a research model placed into the market.

A laboratory scientist analyzing a biological sample with digital tools
Research becomes an application Measurement, analysis and validation turn a biological pattern into a focused test.
01 · DISCOVER

Investigate the signal

Identify biologically and analytically meaningful microRNA patterns in relevant datasets.

02 · VALIDATE

Test the model

Evaluate performance, limitations and generalizability in appropriate samples and cohorts.

03 · FOCUS

Define the application

Specify the intended use, test workflow and the focused signal set required for that question.

04 · SUPPORT

Connect to care

Present results with clear limitations and appropriate pathways for physician-led follow-up.

Product clarity

Understand what the test is and what it is not.

miCheckup is

An early cancer detection test.

  • Grounded in peer-reviewed microRNA research
  • Designed to provide screening information
  • Intended to complement established screening and medical care
  • Supported by test-specific guidance on the miCheckup website
miCheckup is not

A diagnosis or replacement for care.

  • It does not diagnose cancer by itself
  • It does not replace recommended screening programs
  • It does not determine treatment
  • Results require appropriate clinical interpretation and follow-up
Continue to the dedicated test website

Cancer-specific information belongs on miCheckup.

Learn who the test is for, how the process works, what the result means and which important limitations to understand.